Improve the management of cancer-related cognitive impairment in clinical settings: a European Delphi study
Mylène Duivon(Inserm), Florence Joly(Inserm), Marie Lange(Inserm), Jean-Baptiste Méric(Institut National du Cancer), Cécile Charles(Université de Bordeaux), Régine Kiasuwa-Mbengi(Sciensano (Belgium)), Giulia Binarelli(Inserm), Isabelle Hardy‐Léger(Hôpital Cochin), Johan Lefel(Centre Henri Becquerel)
Cited by 3
Related Papers
BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET Study
|Journal of Clinical Oncology|2018|330
An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32)
|European Journal of Cancer|2005|241
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
|Nature Medicine|2021|115
Cancer-related cognitive impairment: current perspectives on the management of cognitive changes following cancer treatment
|Expert Review of Neurotherapeutics|2023|31
Cancer-related cognitive impairment in non-CNS cancer patients: Targeted review and future action plans in Europe
|Critical Reviews in Oncology/Hematology|2022|29